VCM
PACB icon

Versant Capital Management’s Pacific Biosciences PACB Stock Holding History

Versant Capital Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-48
Closed -$638 – 2019
2023
Q2 		$638 Buy
+48
New +$583 ﹤0.01% 1755

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Versant Capital Management's PACB Position: Q3 2023 in Review

Versant Capital Management sold out of Pacific Biosciences (PACB) in Q3 2023, closing a stake of 48 shares — an estimated $638 sold.

Versant Capital Management first reported a position in PACB in Q2 2023 and held it in 1 quarter. The position peaked at $638 in Q2 2023. 274 funds tracked by Wall St. Rank hold PACB as of Q3 2023.

  • Versant Capital Management reported no remaining Pacific Biosciences position as of Q3 2023 after selling out during the quarter.
  • Versant Capital Management sold 48 Pacific Biosciences shares in Q3 2023, an estimated $638.
  • Versant Capital Management first reported a position in Pacific Biosciences in Q2 2023 and held it in 1 quarter.
  • Versant Capital Management's Pacific Biosciences position peaked at $638 in Q2 2023.
  • 274 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2023.

Based on Versant Capital Management's 13F filing for Q3 2023, filed 12 Oct 2023.